MicroRNA biomarker identification for pediatric acute myeloid leukemia based on a novel bioinformatics model

Oncotarget
Wenying YanBairong Shen

Abstract

Acute myeloid leukemia (AML) in children is a complex and heterogeneous disease. The identification of reliable and stable molecular biomarkers for diagnosis, especially early diagnosis, remains a significant therapeutic challenge. Aberrant microRNA expression could be used for cancer diagnosis and treatment selection. Here, we describe a novel bioinformatics model for the prediction of microRNA biomarkers for the diagnosis of paediatric AML based on computational functional analysis of the microRNA regulatory network substructure. microRNA-196b, microRNA-155 and microRNA-25 were identified as putative diagnostic biomarkers for pediatric AML. Further systematic analysis confirmed the association of the predicted microRNAs with the leukemogenesis of AML. In vitro q-PCR experiments showed that microRNA-155 is significantly overexpressed in children with AML and microRNA-196b is significantly overexpressed in subgroups M4-M5 of the French-American-British classification system. These results suggest that microRNA-155 is a potential diagnostic biomarker for all subgroups of paediatric AML, whereas microRNA-196b is specific for subgroups M4-M5.

References

Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Aug 31, 2000·Annual Review of Biochemistry·T Hirano
Apr 28, 2006·Proceedings of the National Academy of Sciences of the United States of America·Stefan CostineanCarlo M Croce
Feb 13, 2007·Proceedings of the National Academy of Sciences of the United States of America·Robert W GeorgantasCurt I Civin
Apr 28, 2007·Science·To-Ha ThaiKlaus Rajewsky
Apr 28, 2007·Science·Antony RodriguezAllan Bradley
Sep 6, 2007·Cell Cycle·Michael CarletonPeter S Linsley
Feb 27, 2008·The Journal of Experimental Medicine·Ryan M O'ConnellDavid Baltimore
Mar 1, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ramiro GarzonBrunangelo Falini
Jun 3, 2008·Trends in Immunology·Mark A Lindsay
Sep 27, 2008·Annual Review of Pathology·Yong Sun Lee, Anindya Dutta
Oct 4, 2008·Proceedings of the National Academy of Sciences of the United States of America·Zejuan LiJianjun Chen
Jan 30, 2010·Blood Cells, Molecules & Diseases·Yungui WangJie Jin
Sep 8, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Sanja DacicMarina N Nikiforova
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ching-Hon PuiRobert J Arceci
May 10, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Xiaoya LuoHermann Brenner
Jun 28, 2011·BMC Systems Biology·Chien-Wei TsengHsueh-Fen Juan
Aug 11, 2012·Blood·Ursula CreutzigUNKNOWN AML Committee of the International BFM Study Group
Apr 9, 2013·Leukemia·A S MooreC M Zwaan
Sep 17, 2013·World Journal of Gastroenterology : WJG·Tao LiLin Chen
Sep 28, 2013·Leukemia·M Díaz-BeyáUNKNOWN Cooperative AML group CETLAM (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias)
Jan 8, 2014·Experimental Cell Research·Molin LiChuangang Li

❮ Previous
Next ❯

Citations

Sep 20, 2019·International Journal of Molecular Sciences·Angela GalardiAngela Di Giannatale
Sep 15, 2016·Cancer Informatics·Wenying YanGuang Hu
Mar 1, 2018·Oncotarget·Oshrat Hershkovitz-RokahStella Liberman-Aronov
Sep 12, 2018·International Journal of Molecular Sciences·Jaqueline Carvalho de OliveiraMaría Sol Brassesco
Jan 4, 2017·BioMed Research International·Yujie ZhuJingjing Shi
Apr 18, 2016·Medical Oncology·Ivna Néria Silva Ribamar de CarvalhoFernando Regla Vargas
Dec 12, 2017·Cancer Biomarkers : Section a of Disease Markers·Ze HongHaixiao Qi
Jun 30, 2018·International Journal of Molecular Medicine·Xiaoyan ZhaoHaibing Wu
Jan 17, 2020·Database : the Journal of Biological Databases and Curation·Rongrong WuBairong Shen
Oct 16, 2016·Journal of Cancer Research and Clinical Oncology·Xiang WangRongrong Zhang
Jun 16, 2016·Clinical Chemistry and Laboratory Medicine : CCLM·Ting-Juan ZhangJun Qian
Feb 10, 2016·Frontiers in Pharmacology·Neha S BhiseJatinder K Lamba
May 23, 2018·Journal of Translational Medicine·Yuxin LinBairong Shen

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

GeneGo
SPSS
Graphpad Prism
POMA
Limma R package
MetaCore
BioConductor
POMA ( Pipeline of Outlier MicroRNA Analysis
affy

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

The New England Journal of Medicine
Guido MarcucciClara D Bloomfield
The New England Journal of Medicine
William J RitchieJohn E J Rasko
World Journal of Gastrointestinal Oncology
Ganepola Ap GanepolaDavid H Chang
© 2021 Meta ULC. All rights reserved